Fierce Biotech

Evofem makes top-to-bottom cuts to save cash, slashing CEO pay by 40% and eliminating positions ntaylor Tue, 03/21/2023 - 08:54

Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon ntaylor Tue, 03/21/2023 - 06:26

Clario partners with Strados to offer respiratory tech for clinical trials jkeenan Mon, 03/20/2023 - 22:16

Ruling on Elizabeth Holmes' prison delay, restitution to Theranos investors pushed back apark Mon, 03/20/2023 - 14:17

Gilead scoops up Nurix’s IRAK4 degrader for up to $445M, plucking first fruit grown from 2019 collab mbayer Mon, 03/20/2023 - 12:12

Athenex's cash dries up as it faces clinical hold on cancer therapy in wake of patient death gmasson Mon, 03/20/2023 - 11:25

Illumina, Icahn trade jabs amid looming proxy fight over $8B Grail buy apark Mon, 03/20/2023 - 10:27

BioNTech's cancer push continues, coughing up $200M for OncoC4's CTLA-4 antibody mbayer Mon, 03/20/2023 - 09:52

Karuna continues to build hype for schizophrenia drug with phase 3 data drop but investors not convinced jwaldron Mon, 03/20/2023 - 09:24

Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years jwaldron Mon, 03/20/2023 - 07:36

Takeda's $4B drug clears psoriasis in one-third of patients, laying down marker in bid to challenge BMS ntaylor Mon, 03/20/2023 - 07:06

Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession ntaylor Mon, 03/20/2023 - 06:02

Cutiss sends skin cells to the International Space Station hfloersh Mon, 03/20/2023 - 02:09

Syneos in AI-focused pact with Microsoft to speed up trials jkeenan Sun, 03/19/2023 - 18:33

BD, Visby Medical snag updated FDA nods for women's health PCR tests apark Fri, 03/17/2023 - 15:21

Pear market: Digital therapeutics maker eyeing a sale in last-ditch money-saving move after layoffs, stock sale apark Fri, 03/17/2023 - 12:54

Return of the megaround: Is biotech back from the brink?  aarmstrong Fri, 03/17/2023 - 11:40

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile mbayer Fri, 03/17/2023 - 10:37

iRhythm COO steps down as $30M ‘business transformation’ plan kicks in apark Fri, 03/17/2023 - 10:13

Cash-strapped Acer sees menopause drug flunk phase 2 trial jwaldron Fri, 03/17/2023 - 10:12